PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update
Author(s): Reuss R
Volume: 2013
Issue: default
Year: 2013
Author(s): Reuss R Volume: 2013 Issue: default Year: 2013
Immunization of rabbits with synthetic peptides derived from a highly conserved β-sheet epitope region underneath the receptor binding site of influenza A virus
Author(s): Ideno S | Sakai K | Yunoki M | Kubota-Koketsu R | Inoue Y | Nakamura S | Yasunaga T | Okuno Y | Ikuta K
Volume: 2013
Issue: default
Year: 2013
Author(s): Ideno S | Sakai K | Yunoki M | Kubota-Koketsu R | Inoue Y | Nakamura S | Yasunaga T | Okuno Y | Ikuta K Volume: 2013 Issue: default Year: 2013
Clinical use of crizotinib for the treatment of non-small cell lung cancer
Author(s): Roberts PJ
Volume: 2013
Issue: default
Year: 2013
Author(s): Roberts PJ Volume: 2013 Issue: default Year: 2013
Tivozanib in the treatment of renal cell carcinoma
Author(s): Hepgur M | Sadeghi S | Dorff TB | Quinn DI
Volume: 2013
Issue: default
Year: 2013
Author(s): Hepgur M | Sadeghi S | Dorff TB | Quinn DI Volume: 2013 Issue: default Year: 2013
Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma
Author(s): Walsh GM
Volume: 2013
Issue: default
Year: 2013
Author(s): Walsh GM Volume: 2013 Issue: default Year: 2013
Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
Author(s): Nooka A | Gleason C | Casbourne D | Lonial S
Volume: 2013
Issue: default
Year: 2013
Author(s): Nooka A | Gleason C | Casbourne D | Lonial S Volume: 2013 Issue: default Year: 2013
Hereditary angioedema: epidemiology, management, and role of icatibant
Author(s): Ghazi A | Grant JA
Volume: 2013
Issue: default
Year: 2013
Author(s): Ghazi A | Grant JA Volume: 2013 Issue: default Year: 2013
A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease
Author(s): Bennett J | Dubois C
Volume: 2013
Issue: default
Year: 2013
Author(s): Bennett J | Dubois C Volume: 2013 Issue: default Year: 2013
Cross-reactivity of human monoclonal antibodies generated with peripheral blood lymphocytes from dengue patients with Japanese encephalitis virus
Author(s): Pipattanaboon C | Sasaki T | Nishimura M | Setthapramote C | Pitaksajjakul P | Leaungwutiwong P | Limkittikul K | Puiprom O | Sasayama M | Chaichana P | Okabayashi T | Kurosu T | Ono K | Ramasoota P | Ikuta K
Volume: 2013
Issue: default
Year: 2013
Author(s): Pipattanaboon C | Sasaki T | Nishimura M | Setthapramote C | Pitaksajjakul P | Leaungwutiwong P | Limkittikul K | Puiprom O | Sasayama M | Chaichana P | Okabayashi T | Kurosu T | Ono K | Ramasoota P | Ikuta K Volume: 2013 Issue: default Year: 2013
Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
Author(s): Keohane C | Radia DH | Harrison CN
Volume: 2013
Issue: default
Year: 2013
Author(s): Keohane C | Radia DH | Harrison CN Volume: 2013 Issue: default Year: 2013
Treatment and management of myelofibrosis in the era of JAK inhibitors
Author(s): Keohane C | Radia DH | Harrison CN
Volume: 2013
Issue: default
Year: 2013
Author(s): Keohane C | Radia DH | Harrison CN Volume: 2013 Issue: default Year: 2013
Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
Author(s): Ansari J | Hussain SA | Ansari A | Glaholm J
Volume: 2013
Issue: default
Year: 2013
Author(s): Ansari J | Hussain SA | Ansari A | Glaholm J Volume: 2013 Issue: default Year: 2013
Cetuximab: its unique place in head and neck cancer treatment
Author(s): Specenier P | Vermorken JB
Volume: 2013
Issue: default
Year: 2013
Author(s): Specenier P | Vermorken JB Volume: 2013 Issue: default Year: 2013
Treatment of hemophilia B: focus on recombinant factor IX
Author(s): Franchini M | Frattini F | Crestani S | Sissa C | Bonfanti C
Volume: 2013
Issue: default
Year: 2013
Author(s): Franchini M | Frattini F | Crestani S | Sissa C | Bonfanti C Volume: 2013 Issue: default Year: 2013
Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer
Author(s): D'Arcangelo M | Cappuzzo F
Volume: 2013
Issue: default
Year: 2013
Author(s): D'Arcangelo M | Cappuzzo F Volume: 2013 Issue: default Year: 2013
Efficacy of intensity-modulated radiotherapy combined with chemotherapy or surgery in locally advanced squamous cell carcinoma of the head-and-neck
Author(s): Yang H | Diao LQ | Shi M | Ma R | Wang JH | Li JP | Xiao F | Xue Y | Xu M | Zhou B
Volume: 2013
Issue: default
Year: 2013
Author(s): Yang H | Diao LQ | Shi M | Ma R | Wang JH | Li JP | Xiao F | Xue Y | Xu M | Zhou B Volume: 2013 Issue: default Year: 2013
Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis
Author(s): Benucci M | Saviola G | Manfredi M | Sarzi-Puttini P | Atzeni F
Volume: 2013
Issue: default
Year: 2013
Author(s): Benucci M | Saviola G | Manfredi M | Sarzi-Puttini P | Atzeni F Volume: 2013 Issue: default Year: 2013
New and emerging treatments for ulcerative colitis: a focus on vedolizumab
Author(s): Gledhill T | Bodger K
Volume: 2013
Issue: default
Year: 2013
Author(s): Gledhill T | Bodger K Volume: 2013 Issue: default Year: 2013
Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis
Author(s): Mathieu S | Couderc M | Glace B | Pereira B | Tournadre A | Dubost JJ | Soubrier M
Volume: 2013
Issue: default
Year: 2013
Author(s): Mathieu S | Couderc M | Glace B | Pereira B | Tournadre A | Dubost JJ | Soubrier M Volume: 2013 Issue: default Year: 2013
NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab [Corrigendum]
Author(s): Lurati A | Bertani L | Marrazza M | Re KA | Bompane D | Scarpellini M
Volume: 2013
Issue: default
Year: 2013
Author(s): Lurati A | Bertani L | Marrazza M | Re KA | Bompane D | Scarpellini M Volume: 2013 Issue: default Year: 2013
Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action
Author(s): Damal K | Stoker E | Foley JF
Volume: 2013
Issue: default
Year: 2013
Author(s): Damal K | Stoker E | Foley JF Volume: 2013 Issue: default Year: 2013
Erythropoiesis stimulating agents approaches to modulate activity
Author(s): Sinclair AM
Volume: 2013
Issue: default
Year: 2013
Author(s): Sinclair AM Volume: 2013 Issue: default Year: 2013
Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex
Author(s): Franz DN
Volume: 2013
Issue: default
Year: 2013
Author(s): Franz DN Volume: 2013 Issue: default Year: 2013
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
Author(s): Ververis K | Hiong A | Karagiannis TC | Licciardi PV
Volume: 2013
Issue: default
Year: 2013
Author(s): Ververis K | Hiong A | Karagiannis TC | Licciardi PV Volume: 2013 Issue: default Year: 2013
Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis
Author(s): Kaushik T | Yaqoob MM
Volume: 2013
Issue: default
Year: 2013
Author(s): Kaushik T | Yaqoob MM Volume: 2013 Issue: default Year: 2013
Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study
Author(s): Cantini F | Niccoli L | Cassara E | Kaloudi O | Nannini C
Volume: 2013
Issue: default
Year: 2013
Author(s): Cantini F | Niccoli L | Cassara E | Kaloudi O | Nannini C Volume: 2013 Issue: default Year: 2013
Bosutinib in the management of chronic myelogenous leukemia
Author(s): Keller-von Amsberg G | Schafhausen P
Volume: 2013
Issue: default
Year: 2013
Author(s): Keller-von Amsberg G | Schafhausen P Volume: 2013 Issue: default Year: 2013
Role of vandetanib in the management of medullary thyroid cancer
Author(s): Brassard M | Rondeau G
Volume: 2012
Issue: default
Year: 2012
Author(s): Brassard M | Rondeau G Volume: 2012 Issue: default Year: 2012
First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
Author(s): Nguyen KS | Neal JW
Volume: 2012
Issue: default
Year: 2012
Author(s): Nguyen KS | Neal JW Volume: 2012 Issue: default Year: 2012
OnabotulinumtoxinA in the treatment of neurogenic bladder
Author(s): Gulamhusein A | Mangera A
Volume: 2012
Issue: default
Year: 2012
Author(s): Gulamhusein A | Mangera A Volume: 2012 Issue: default Year: 2012
B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
Author(s): Wiesik-Szewczyk E | Olesinska M
Volume: 2012
Issue: default
Year: 2012
Author(s): Wiesik-Szewczyk E | Olesinska M Volume: 2012 Issue: default Year: 2012
Ovarian cancer: emerging molecular-targeted therapies
Author(s): Sourbier C
Volume: 2012
Issue: default
Year: 2012
Author(s): Sourbier C Volume: 2012 Issue: default Year: 2012
Potential role of 124I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer
Author(s): Smaldone MC | Chen DY | Yu JQ | Plimack ER
Volume: 2012
Issue: default
Year: 2012
Author(s): Smaldone MC | Chen DY | Yu JQ | Plimack ER Volume: 2012 Issue: default Year: 2012
Role of CD44 as a marker of cancer stem cells in head and neck cancer
Author(s): Trapasso S | Allegra E
Volume: 2012
Issue: default
Year: 2012
Author(s): Trapasso S | Allegra E Volume: 2012 Issue: default Year: 2012
Significant neutralizing activities against H2N2 influenza A viruses in human intravenous immunoglobulin lots manufactured from 1993 to 2010
Author(s): Kubota-Koketsu R | Yunoki M | Okuno Y | Ikuta K
Volume: 2012
Issue: default
Year: 2012
Author(s): Kubota-Koketsu R | Yunoki M | Okuno Y | Ikuta K Volume: 2012 Issue: default Year: 2012
Prevalence of OmpK35 and OmpK36 porin expression in beta-lactamase and non-beta-lactamase-producing Klebsiella pneumoniae
Author(s): Shakib P | Ghafourian S | Zolfaghary MR | Hushmandfar R | Ranjbar R | Sadeghifard N
Volume: 2012
Issue: default
Year: 2011
Author(s): Shakib P | Ghafourian S | Zolfaghary MR | Hushmandfar R | Ranjbar R | Sadeghifard N Volume: 2012 Issue: default Year: 2011
Monoclonal antibodies and Fc fragments for treating solid tumors
Author(s): Eisenbeis AM | Grau SJ
Volume: 2012
Issue: default
Year: 2012
Author(s): Eisenbeis AM | Grau SJ Volume: 2012 Issue: default Year: 2012
Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study
Author(s): Cantini F | Niccoli L | Cassarà E | Kaloudi O | Nannini C
Volume: 2012
Issue: default
Year: 2012
Author(s): Cantini F | Niccoli L | Cassarà E | Kaloudi O | Nannini C Volume: 2012 Issue: default Year: 2012
Emerging role of multikinase inhibitors for refractory thyroid cancer
Author(s): Perez CA | Arango BA | Velez M | Raez LE | Santos ES
Volume: 2012
Issue: default
Year: 2012
Author(s): Perez CA | Arango BA | Velez M | Raez LE | Santos ES Volume: 2012 Issue: default Year: 2012
Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure
Author(s): Kekow J | Mueller-Ladner U | Schulze-Koops H
Volume: 2012
Issue: default
Year: 2012
Author(s): Kekow J | Mueller-Ladner U | Schulze-Koops H Volume: 2012 Issue: default Year: 2012
Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70
Author(s): Orme ME | MacGilchrist KS | Mitchell S | Spurden D | Bird A
Volume: 2012
Issue: default
Year: 2012
Author(s): Orme ME | MacGilchrist KS | Mitchell S | Spurden D | Bird A Volume: 2012 Issue: default Year: 2012
Clinical use of biologics in vasculitis syndromes
Author(s): Paroli M
Volume: 2012
Issue: default
Year: 2012
Author(s): Paroli M Volume: 2012 Issue: default Year: 2012
The small leucine-rich proteoglycan, biglycan, is highly expressed in adipose tissue of Psammomys obesus and is associated with obesity and type 2 diabetes
Author(s): Bolton K | Segal D | Walder K
Volume: 2012
Issue: default
Year: 2012
Author(s): Bolton K | Segal D | Walder K Volume: 2012 Issue: default Year: 2012
Limited cross-reactivity of mouse monoclonal antibodies against Dengue virus capsid protein among four serotypes
Author(s): Noda M | Masrinoul P | Punkum C | Pipattanaboon C | Ramasoota P | Setthapramote C | Sasaki T | Sasayama M | Yamashita A | Kurosu T | Ikuta K | Okabayashi T
Volume: 2012
Issue: default
Year: 2012
Author(s): Noda M | Masrinoul P | Punkum C | Pipattanaboon C | Ramasoota P | Setthapramote C | Sasaki T | Sasayama M | Yamashita A | Kurosu T | Ikuta K | Okabayashi T Volume: 2012 Issue: default Year: 2012
Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis
Author(s): Hasan E | Olusi S | Al-Awadhi A | Mokaddem K | Sharma P | George S
Volume: 2012
Issue: default
Year: 2012
Author(s): Hasan E | Olusi S | Al-Awadhi A | Mokaddem K | Sharma P | George S Volume: 2012 Issue: default Year: 2012
Natural killer cells: role in local tumor growth and metastasis
Author(s): Langers I | Renoux VM | Thiry M | Delvenne P | Jacobs N
Volume: 2012
Issue: default
Year: 2012
Author(s): Langers I | Renoux VM | Thiry M | Delvenne P | Jacobs N Volume: 2012 Issue: default Year: 2012
Clofilium inhibits Slick and Slack potassium channels
Author(s): Tejada MA | Stolpe K | Meinild AK | Klaerke DA
Volume: 2012
Issue: default
Year: 2012
Author(s): Tejada MA | Stolpe K | Meinild AK | Klaerke DA Volume: 2012 Issue: default Year: 2012
Effect of biologic therapy on radiological progression in rheumatoid arthritis: what does it add to methotrexate?
Author(s): Jones G | Darian-Smith E | Kwok M | Winzenberg T
Volume: 2012
Issue: default
Year: 2012
Author(s): Jones G | Darian-Smith E | Kwok M | Winzenberg T Volume: 2012 Issue: default Year: 2012
Local pulmonary administration of factor VIIa (rFVIIa) in diffuse alveolar hemorrhage (DAH) – a review of a new treatment paradigm
Author(s): Heslet L | Nielsen JD | Nepper-Christensen S
Volume: 2012
Issue: default
Year: 2012
Author(s): Heslet L | Nielsen JD | Nepper-Christensen S Volume: 2012 Issue: default Year: 2012
Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant kidney rejection
Author(s): Ippoliti G | D'Armini AM | Lucioni M | Marjieh M | Viganò M
Volume: 2012
Issue: default
Year: 2012
Author(s): Ippoliti G | D'Armini AM | Lucioni M | Marjieh M | Viganò M Volume: 2012 Issue: default Year: 2012